Cancer Chemotherapy and Pharmacology

, Volume 72, Issue 1, pp 101–107

A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma

  • Lisa N. Abaid
  • John P. Micha
  • Mark A. Rettenmaier
  • John V. Brown
  • Alberto A. Mendivil
  • Katrina L. Lopez
  • Bram H. Goldstein
Original Article



Traditional dose-dense chemotherapy regimens for advanced stage ovarian cancer incorporate weekly paclitaxel on a 21-day cycle and are associated with favorable efficacy but high rates of neutropenia, thrombocytopenia, and anemia. The purpose of this phase II study was to assess the response rate and toxicity of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage ovarian, fallopian tube, and primary peritoneal carcinoma.


All eligible patients were treated with 6 cycles of intravenous dose-dense paclitaxel (80 mg/m2) days 1, 8, and 15 and carboplatin (AUC 5 or 6) Day 1 during a 28-day cycle in accordance with an IRB-approved protocol. Patients who had clinically defined stable disease or better with a CA-125 ≤ 35 U/ml following the completion of primary induction therapy were subsequently administered a planned 12 cycles of paclitaxel (135 mg/m2; every 21 days) consolidation therapy.


Eighty-eight patients received at least 3 cycles of induction dose-dense chemotherapy, of whom 76 completed 6 cycles of chemotherapy; the overall response rate was 84.2 % (56.6 % complete response). Fifty-three patients received an aggregate 473 cycles (median = 9; range 1–12) of consolidation chemotherapy. Grade 3–4 hematological toxicity included neutropenia (22.7 %), thrombocytopenia (7.9 %), and anemia (1.1 %). Further, grade 3 neuropathy developed in one (1.1 %) patient. The patients’ median disease-free survival and overall survival were 22.5 and 31.5 months, respectively.


This phase II study suggests that first-line treatment comprising modified dose-dense paclitaxel and monthly carboplatin chemotherapy with paclitaxel consolidation therapy preserves the efficacy of traditional dose-dense chemotherapy, while minimizing hematologic toxicity.


Gynecologic oncology Ovarian cancer Dose-dense chemotherapy Paclitaxel Carboplatin 


  1. 1.
    Jemal A, Bray F, Center MM et al (2011) Cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  2. 2.
    Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200PubMedCrossRefGoogle Scholar
  3. 3.
    Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691PubMedCrossRefGoogle Scholar
  4. 4.
    Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649PubMedCrossRefGoogle Scholar
  5. 5.
    Safra T, Menczer J, Bernstein RM et al (2009) Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Gynecol Oncol 114:215–218PubMedCrossRefGoogle Scholar
  6. 6.
    Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331–1338PubMedCrossRefGoogle Scholar
  7. 7.
    Oskay-Ozcelik G, Chekerov R, Sommer H et al (2010) Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology. Gynecol Oncol 116:317–322PubMedCrossRefGoogle Scholar
  8. 8.
    Burris H III, Yardley D, Jones S, Thompson D, Greco FA, White M, Hainsworth J et al (2004) Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22:1621–1629PubMedCrossRefGoogle Scholar
  9. 9.
    Wu CH, Yang CH, Lee JN et al (2001) Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. Int J Gynecol Cancer 11:295–299PubMedCrossRefGoogle Scholar
  10. 10.
    Shen K, Li MD, Feng YJ et al (2005) A multicenter randomized clinical trial of weekly paclitaxel and carboplatin versus three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer. Zhonghua Yi Xue Za Zhi 85:2099–2103PubMedGoogle Scholar
  11. 11.
    Markman M, Blessing J, Rubin SC et al (2006) Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101:436–440PubMedCrossRefGoogle Scholar
  12. 12.
    Bookman MA (2009) Dose-dense chemotherapy in advanced ovarian cancer. Lancet 374:1303–1305PubMedCrossRefGoogle Scholar
  13. 13.
    Brown JV III, Micha JP, Rettenmaier MA et al (2010) A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer 20:1132–1136PubMedCrossRefGoogle Scholar
  14. 14.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108:276–281PubMedCrossRefGoogle Scholar
  15. 15.
    Bookman MA, Brady MF, McGuire WP et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419–1425PubMedCrossRefGoogle Scholar
  16. 16.
    Brown JV, Rettenmaier MA, Dillman RA et al (1998) Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer. Gynecol Oncol 68:166–168PubMedCrossRefGoogle Scholar
  17. 17.
    Hainsworth JD, Greco F (1994) Paclitaxel administered by 1-hour infusion. Cancer 74:1377–1382PubMedCrossRefGoogle Scholar
  18. 18.
    Calvert AH, Newell DR, Gunbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMedGoogle Scholar
  19. 19.
    Jelliffe RW (1973) Creatinine clearance: bedside estimate. Ann Intern Med 79:605CrossRefGoogle Scholar
  20. 20.
    NIH (2010) Common terminology criteria for adverse events (version 4.03). Washington: National Institute of HealthGoogle Scholar
  21. 21.
    López-Pousa A, Rifà J, Casas de Tejerina A et al (2010) Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. Eur J Cancer Care 19:648–655CrossRefGoogle Scholar
  22. 22.
    Markman M, Liu PY, Wilczynski S et al (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a southwest oncology group and gynecologic oncology group trial. J Clin Oncol 21:2460–2465PubMedCrossRefGoogle Scholar
  23. 23.
    Micha JP, Goldstein BH, Graham C et al (2006) Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma. Oncology 71:49–53PubMedCrossRefGoogle Scholar
  24. 24.
    Therasse P, Arbuck SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  25. 25.
    Rustin GJ, Marples M, Nelstrop AE (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19:4054–4057PubMedGoogle Scholar
  26. 26.
    Eltabbakh GH (2004) Recent advances in the management of women with ovarian cancer. Minerva Ginecol 56:81–89PubMedGoogle Scholar
  27. 27.
    Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21:149s–167sPubMedCrossRefGoogle Scholar
  28. 28.
    Sehouli J, Stengel D, Mustea A et al (2008) Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol 61:243–250PubMedCrossRefGoogle Scholar
  29. 29.
    Armstrong DK, Bookman MA, McGuire W (2007) A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 105:667–671PubMedCrossRefGoogle Scholar
  30. 30.
    Liu PY, Alberts DS, Monk BJ et al (2007) An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 25:3615–3620PubMedCrossRefGoogle Scholar
  31. 31.
    Micha JP, Goldstein BH, Rettenmaier MA et al (2009) Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. Int J Gynecol Cancer 19:239–241PubMedCrossRefGoogle Scholar
  32. 32.
    Abaid LN, Goldstein BH, Micha JP et al (2010) Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology 78:389–393PubMedCrossRefGoogle Scholar
  33. 33.
    Elattar A, Bryant A, Winter-Roach BA et al (2011) Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 10:CD007565Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Lisa N. Abaid
    • 1
  • John P. Micha
    • 1
  • Mark A. Rettenmaier
    • 1
  • John V. Brown
    • 1
  • Alberto A. Mendivil
    • 1
  • Katrina L. Lopez
    • 2
  • Bram H. Goldstein
    • 1
  1. 1.Gynecologic Oncology AssociatesNewport BeachUSA
  2. 2.The Women’s Cancer Research FoundationNewport BeachUSA

Personalised recommendations